GNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year partnership to leverage the longitudinal multi-modal patient registry data from the MMRF CoMMpass Study, the largest genomics data set of any cancer, with GNS’ causal AI and simulation platform to create the next generation of individual patient level computer models of disease progression and drug response. The collaboration will address key questions for multiple myeloma patients, including identifying subtypes of aggressive disease progression and drivers of patient response to an increasing array of therapeutics, including emerging immunotherapies such as CAR-T cell therapy.
“The mission of the MMRF is to cure each and every multiple myeloma patient. With a highly diverse patient population, we need a critical mass of high-quality, longitudinal patient data to achieve that mission. But data by itself doesn’t generate the insights needed to change patient outcomes. This collaboration with GNS will maximize the insights we can extract from CoMMpass data to address questions most critical to patients and the multiple myeloma community,” said Paul Giusti, President and CEO of the MMRF.
“The MMRF has had a tremendous impact on the field and on patients through their data and precision medicine stewardship. As we embark on building the next generation of in silico patient computer models to unravel the drivers of multiple myeloma, their support and collaboration helps us not only to continue uncovering the underlying drivers of the disease but also better simulate which treatments will lead to better outcomes for which patients – getting at the crux of precision medicine in practice,” said Colin Hill, CEO and Co-founder of GNS Healthcare.